Chenodeoxycholic acid
- Generic Name
- Chenodeoxycholic acid
- Brand Names
- Chenodal, Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 474-25-9
- Unique Ingredient Identifier
- 0GEI24LG0J
- Background
Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.
- Indication
Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.
- Associated Conditions
- Radiolucent Cholesterol gallstones
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
- Conditions
- Cerebrotendinous Xanthomatoses
- Interventions
- Drug: Chenodeoxycholic acid Placebo
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06260748
- Locations
- 🇮🇱
Sheba Medical Center, Tel HaShomer, Israel
Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)
- Conditions
- Cerebrotendinous Xanthomatoses
- Interventions
- Drug: Chenodeoxycholic acid leadiant
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Humanis Saglık Anonim Sirketi
- Target Recruit Count
- 24
- Registration Number
- NCT06180057
- Locations
- 🇯🇴
ACDIMA Biocenter, Amman, Jordan
Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
- Conditions
- Cerebrotendinous Xanthomatoses
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Leadiant Biosciences Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05499026
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
- Conditions
- CTX
- Interventions
- Drug: Blinded CDCA 250 mg TIDDrug: PlaceboDrug: Open-Label CDCA 250 mg TIDDrug: Rescue Medication CDCA 250 mg TID
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04270682
- Locations
- 🇧🇷
Travere Investigational Site, São Paulo, SP, Brazil
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
- Conditions
- Bile Acid MalabsorptionCholelithiasis
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT03168555
- Locations
- 🇩🇰
Zealand University Hospital, Køge, Denmark
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02952963
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, DK, Denmark
Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Severe Obesity
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02876484
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Severe Obesity
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT02340247
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Effect of Bile Acids on GLP-1 Secretion
- Conditions
- Type 2 DiabetesObesity
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT01666223
- Locations
- 🇩🇰
Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Copenhagen, Denmark
Cheno Effect on Transit in Health and IBS-C
- Conditions
- Constipation-predominant Irritable Bowel Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00912301
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.